C260-1321 Screening compound: N-[2-(3,4-dimethoxyphenyl)ethyl]-4-{1-[2-(3,5-dimethylpiperidin-1-yl)-2-oxoethyl]-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl}butanamide

C260-1321 Screening compound: N-[2-(3,4-dimethoxyphenyl)ethyl]-4-{1-[2-(3,5-dimethylpiperidin-1-yl)-2-oxoethyl]-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl}butanamide
C260-1321 Screening compound: N-[2-(3,4-dimethoxyphenyl)ethyl]-4-{1-[2-(3,5-dimethylpiperidin-1-yl)-2-oxoethyl]-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl}butanamide alternative view

Chemical Structure Depiction of ChemDiv screening compound C260-1321
N-[2-(3,4-dimethoxyphenyl)ethyl]-4-{1-[2-(3,5-dimethylpiperidin-1-yl)-2-oxoethyl]-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl}butanamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

C260-1321

Molecular Formula

C31H40N4O6 (C31 H40 N4 O6)

Compound Name

N-[2-(3,4-dimethoxyphenyl)ethyl]-4-{1-[2-(3,5-dimethylpiperidin-1-yl)-2-oxoethyl]-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-3-yl}butanamide

IUPAC name

N-[2-(34-dimethoxyphenyl)ethyl]-4-{1-[2-(35-dimethylpiperidin-1-yl)-2-oxoethyl]-24-dioxo-1234-tetrahydroquinazolin-3-yl}butanamide

SMILES

CC(CC(C)C1)CN1C(CN(c(cccc1)c1C(N1CCCC(NCCc(cc2)cc(OC)c2OC)=O)=O)C1=O)=O

InChI

InChI=1S/C31H40N4O6/c1-21-16-22(2)19-33(18-21)29(37)20-35-25-9-6-5-8-24(25)30(38)34(31(35)39)15-7-10-28(36)32-14-13-23-11-12-26(40-3)27(17-23)41-4/h5-6,8-9,11-12,17,21-22H,7,10,13-16,18-20H2,1-4H3,(H,32,36)

InChI Key

DMXIVRUBTMDYTJ-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD14737778

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

564.68

Hydrogen Bond Acceptors Count

10.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

13.00

Number of Nitrogen and Oxygen Atoms

10

Partition Coefficient, logP

1.800

Distribution Coefficient, logD

1.800

Water Solubility, LogSw

-2.79

Polar Surface Area

87.078

Acid Dissociation Constant (pKa)

14.38

Base Dissociation Constant (pKb)

0.57

Number of Chiral Centers

2.00

Percent sp3 carbon bonding

48.40

C260-1321 in Drug Discovery

Included in Screening Libraries

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

Regenerative Medicine Focused Library (23016 compounds)

MCE-18 Trends in Medicinal Chemistry (51288 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Musculoskeletal
  • Digestive system
  • Hemic and lymphatic
  • Cardiovascular
  • Skin
  • wounds

References: we are preparing a list of scientific research reports with C260-1321 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound C260-1321?
Check Price and Availability of C260-1321, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of C260-1321 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for C260-1321
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for C260-1321
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of C260-1321 available by request